摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-甲基吡啶-5-硼酸频哪醇酯 | 1171891-42-1

中文名称
3-甲基吡啶-5-硼酸频哪醇酯
中文别名
5-甲基吡啶-3-基硼酸频那醇酯
英文名称
3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
英文别名
5-methylpyridin-3-ylboronic acid pinacol ester
3-甲基吡啶-5-硼酸频哪醇酯化学式
CAS
1171891-42-1
化学式
C12H18BNO2
mdl
——
分子量
219.091
InChiKey
SYEVQHAWWSEMRN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    327.4±30.0 °C(Predicted)
  • 密度:
    1.02±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.69
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    存储条件为2-8°C,并需保存在惰性气体中。

SDS

SDS:4a3e4dac1f8d2e99cc86b5fa04a85dad
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Methylpyridine-3-boronic acid pinacol ester
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methylpyridine-3-boronic acid pinacol ester
CAS number: 1171891-42-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H18BNO2
Molecular weight: 219.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    3-甲基吡啶-5-硼酸频哪醇酯copper(ll) bromide 作用下, 以 甲醇 为溶剂, 以144 mg的产率得到3-溴-5-甲基吡啶
    参考文献:
    名称:
    通过铱催化的芳烃硼化反应 1,3-二取代芳烃的间位卤化
    摘要:
    我们报告了 1,3-二取代芳烃的间位卤化,通过使用铱催化的芳烃硼化化学形成 3,5-二取代芳基溴化物和氯化物。铱催化的芳烃与 B2pin2 发生硼化反应,然后硼酸酯与溴化铜或氯化铜 (II) 反应,将芳基硼酸酯转化为相应的芳基卤化物。各种含有烷氧基、烷基、卤素、腈、酯、酰胺和新戊酰基的芳烃和 TIPS 保护的醇以 46% 到 85% 的产率转化为相应的 3,5-二取代芳基溴化物和氯化物。此外,2,6-二取代和3-取代吡啶分别转化为4-卤代和5-卤代吡啶。
    DOI:
    10.1021/ja076498n
  • 作为产物:
    描述:
    3-溴-5-甲基吡啶联硼酸频那醇酯tris-(dibenzylideneacetone)dipalladium(0)potassium acetate2-二环己基磷-2,4,6-三异丙基联苯 作用下, 以 1,4-二氧六环 为溶剂, 反应 20.0h, 以60%的产率得到3-甲基吡啶-5-硼酸频哪醇酯
    参考文献:
    名称:
    基于叔芳基 α-螺旋模拟物的模块化合成,第 5 部分:一整套具有蛋白原性氨基酸侧链的吡啶硼酸频哪醇酯
    摘要:
    报道了一组 5-取代的 3-吡啶硼酸频哪醇酯,其侧链修饰有与蛋白质-蛋白质相互作用相关的所有蛋白原氨基酸的侧链。这项工作完成了我们对构建模块库的努力,该库用于通过顺序 Pd 交叉耦合对基于 teraryl 的 α-helix 模拟物进行模块化组装。
    DOI:
    10.1002/ejoc.202101280
点击查看最新优质反应信息

文献信息

  • [EN] TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS<br/>[FR] DÉRIVÉS DE TROPOLONE ET LEURS TAUTOMÈRES POUR LA RÉGULATION DU FER CHEZ LES ANIMAUX
    申请人:AMBYS MEDICINES INC
    公开号:WO2021076945A1
    公开(公告)日:2021-04-22
    Disclosed are a series of compounds or their tautomers having a general structure represented by Formula la or lb and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising said compounds or tautomers or pharmaceutically acceptable salts thereof. Further disclosure relates to a method of treating a disease or condition associated with iron dysregulation or dysfunctional iron homeostasis, comprising administering to a subject in need thereof a therapeutically effective amount of Formula la or lb compounds or tautomers or pharmaceutically acceptable salts thereof.
    本文披露了一系列化合物或其互变异构体,其具有由化学式Ia或Ib表示的一般结构以及其药学上可接受的盐。还披露了包括所述化合物或互变异构体或其药学上可接受的盐的药物组合物。进一步的披露涉及一种治疗与铁调节失调或铁稳态功能异常相关的疾病或症状的方法,包括向需要的受试者施用化学式Ia或Ib化合物或互变异构体或其药学上可接受的盐的治疗有效量。
  • 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
    申请人:KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY 한국과학기술연구원(319980077518) BRN ▼209-82-03522
    公开号:KR20200076655A
    公开(公告)日:2020-06-29
    본 발명은 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체(hydrazone derivatives) 및 이의 용도에 관한 것이다.
    这项发明涉及末端氨基被芳基或杂芳基取代的新的腙衍生物(hydrazone derivatives)及其用途。
  • [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE
    申请人:CARNA BIOSCIENCES INC
    公开号:WO2021130638A1
    公开(公告)日:2021-07-01
    The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症(包括实体瘤)和病毒感染(如HIV或乙型肝炎病毒感染)的药物组合物。这些化合物可以单独使用或与其他药物联合使用。
  • [EN] QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLINE ET DE QUINOXALINE À TITRE D'INHIBITEURS DE KINASES
    申请人:UCB PHARMA SA
    公开号:WO2012032334A1
    公开(公告)日:2012-03-15
    A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    一系列含有氟乙基侧链的喹啉和喹啉衍生物,作为选择性P13激酶酶抑制剂,在医学上具有益处,例如在治疗炎症性、自身免疫性、心血管、神经退行性、代谢性、肿瘤学、疼痛或眼科疾病方面。
  • Iridium-Catalyzed C–H Borylation of Heteroarenes: Scope, Regioselectivity, Application to Late-Stage Functionalization, and Mechanism
    作者:Matthew A. Larsen、John F. Hartwig
    DOI:10.1021/ja412563e
    日期:2014.3.19
    from the olefin-bound complex observed during arene borylation to a species containing a bound heteroarene, leading to catalyst deactivation. Studies on the origins of the observed regioselectivity show that borylation occurs distal to N-H bonds due to rapid N-H borylation, creating an unfavorable steric environment for borylation adjacent to these bonds. Computational studies and mechanistic studies show
    报道了铱催化杂芳烃的 CH 硼化的研究。发现几种含有多个杂原子的杂芳烃适合由铱 (I) 前体和四甲基菲咯啉的组合催化的 CH 硼化。对反应范围的研究导致了预测硼化的区域选择性的强大规则的发展,其中最重要的是硼化发生在氮原子的远端。报告了原位形成的杂芳基硼酸酯的一锅官能化,证明了所报告的方法对合成复杂杂芳基结构的有用性。还展示了这种方法在生物活性化合物的合成和后期功能化中的应用。机理研究表明,碱性杂芳烃可以与催化剂结合,并将在芳烃硼化过程中观察到的烯烃结合复合物的静止状态改变为含有结合杂芳烃的物质,从​​而导致催化剂失活。对观察到的区域选择性起源的研究表明,由于快速的 NH 硼酸化,硼酸化发生在 NH 键的远端,为与这些键相邻的硼酸化创造了不利的空间环境。计算研究和机理研究表明,与碱性氮相邻的 CH 键缺乏可观察到的硼化并不是在 CH 活化之前与庞大的路易斯酸配位的结果,
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-